Clinical Trial Update: ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gefitinib (IRESSA) in combination with docetaxel and cisplatin for metastatic head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: AstraZeneca | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED